October Recap 2025
We are back with another monthly post for our paid subscribers. In this post, we also share a number of fun things that are more personal, interesting, and meant to create a closer community around RxTeach.
We are back with another monthly post for our paid subscribers. In this post, we also share a number of fun things that are more personal, interesting, and meant to create a closer community around RxTeach. We hope you enjoy it! If you're only interested in our free content, that's great! We will never put up a paywall for all of our posts. With that in mind, if you want to help fund disease prevention and research efforts, this is your chance! Reminder that all profits are donated to preventative medicine education and cancer research through student scholarships. We're excited about this chance to contribute to some of the efforts that we care about most and we genuinely hope you consider contributing!
Article Recaps
- Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms, driven mainly by JAK2, CALR, or MPL mutations.
- Diagnosis requires bone marrow fibrosis, exclusion of other neoplasms, and detection of a clonal marker per WHO 2022 criteria.
- Prognosis varies widely and is assessed using scoring systems such as IPSS/DIPSS, which incorporate clinical, cytogenetic, and molecular factors.
- Treatment focuses on symptom control with JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), with allogeneic HSCT as the only curative option; emerging therapies aim to achieve disease modification and improved survival.